NEW YORK (Reuters Health) Jan 24 - The extended-spectrum triazole posaconazole appears to be more effective than fluconazole as prophylaxis among patients at risk for invasive fungal infections, particularly those due to invasive disease, according to two international, point in time III trials reported in the January 25th military issue of The New England Writing of Medical science. Natural selection may also be good when posaconazole is used.
Dr. Andrew J. Ullmann, at the Johannes Gutenberg Body in Mainz, Germany, and associates compared the two drugs between 1999 and 2003 as a prophylaxis among 600 patients with graft-versus-host disease after stem-cell transplanting and immunosuppressive therapy.
The patients were treated at 90 centers were randomized to receive posaconazole oral interruption (Noxafil, Schering-Plough) at a dose of 200 mg digit second daily, or a fluconazole encapsulated bar (Diflucan, Pfizer) 400 mg once daily. Subjects also took medicinal drug treatments so that therapies appeared to mates. Tending lasted for up to 112 days.